Dr. Corinne Ramos, Executive Director of Clinical Research, will be presenting “Case Histories in RPPA Personalized Therapy” on October 13, 2015 at the 2015 Global RPPA Workshop.
Theranostics Health, Inc. and its collaborators are presenting functional proteomic results on the use of the TheraLink® Assay at the 2015 Breast Cancer Symposium being held at the San Francisco Marriott Marquis on September 25-26.
Joyce A. O’Shaughnessy, MD, of the Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses the use of phosphoprotein analysis in decision-making for triple negative breast cancer patients. She highlights a subset of triple negative breast cancer patients with elevated phospho-EGFR and activated downstream signaling pathways, as determined by proteomic analysis, who responded to anti-EGFR directed therapies.
To learn more about phosphoprotein testing of breast cancer using the TheraLink® Assay for Breast Cancer or to order a test.
Theranostics Health announced today that its CAP-CLIA laboratory has been awarded the California Clinical Laboratory License from the California Department of Health that will allow it to begin offering TheraLink® Assay analysis services to cancer patients in the State of California.
To read the press release: Theranostics Health CA Clinical Lab Permit
Theranostics Health, Inc. and its collaborators are presenting results on the use of the TheraLink® Assay to assess drug target and pathway activation to predict drug response and resistance in key breast cancer clinical populations.
To read more: Theranostics_Announcement_2015 ASCO Posters
2:50 pm, Tuesday May 5, 2015
Loews Philadelphia Hotel
Glenn Hoke, Ph.D., Executive Vice President and COO, is providing a presentation on the TheraLink®Assay for Breast Cancer titled “A novel Phospho-Proteomic Diagnostic for Patient Stratification and Therapy Selection for Breast Cancer” at the Biomarker World Congress.
Theranostics Health, Inc., announced today a series of agreements to expand on current research and commercial collaborations with Avera Health to assess the TheraLink® Assay technologies as a proteomic-based personalized medicine tool in breast cancer, and to help explore its potential utility in a number of other key cancers.
To read more: Avera Health TheraLink® Technology Collaboration
Theranostics Health, Inc., announced today the launch of a greatly enhanced TheraLink® Assay Panel for Breast Cancer that incorporates several improvements in its ability to identify the best therapeutic choices for treating patients with advanced, refractory, or inflammatory breast cancer.
To read more: TheraLink® Assay Expansion for Breast Cancer
Theranostics Health Inc. announces today a joint publication with the Georgetown Lombardi Cancer Center in the American Cancer Society’s journal Cancer of “A Phase 1 Study of Cetuximab and Lapatinib in Patients with Advanced Solid Tumor Malignancies” that supports the use of measuring drug target up-regulation and activation to predict response to therapy.
Theranostics Health welcomes the appointment of five preeminent medical researchers to its Medical Advisory Board (MAB).
- Brian Leyland-Jones, MD serves as Vice President of Molecular and Experimental Medicine with Avera Medical Group. Dr. Leyland-Jones will Chair the MAB.
- Massimo Cristofanilli, MD serves as Director of the Jefferson Breast Care Center at the Kimmel Cancer Center and Thomas Jefferson University and Hospital.
- Lance Liotta, MD, PhD serves as University Professor and Co-Director Center for Applied Proteomics and Molecular Medicine at George Mason University.
- Joyce O’Shaughnessy, MD serves as Co-Chair of Breast Cancer Research at Baylor-Sammons Cancer Center and for the US Oncology Network.
- Neil L. Spector, MD, serves as Associate Professor of Medicine, Pharmacology & Cancer Biology at the Duke University School of Medicine.